tiprankstipranks
Trending News
More News >
AnteoTech Ltd (AU:ADO)
ASX:ADO
Australian Market
Advertisement

AnteoTech Ltd (ADO) AI Stock Analysis

Compare
16 Followers

Top Page

AU:ADO

AnteoTech Ltd

(Sydney:ADO)

Rating:44Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
The overall stock score for AnteoTech Ltd is primarily influenced by its poor financial performance, characterized by persistent losses and negative cash flows. Technical analysis suggests a bearish trend with potential correction risks due to overbought conditions. Valuation metrics further highlight concerns, with a negative P/E ratio and no dividend yield.

AnteoTech Ltd (ADO) vs. iShares MSCI Australia ETF (EWA)

AnteoTech Ltd Business Overview & Revenue Model

Company DescriptionAnteoTech Limited, a surface chemistry company, develops, commercializes, manufactures, and distributes products for the life sciences, diagnostics, energy, and medical device markets primarily in Australia. Its products include AnteoBind ready-to-use kits to streamline and enhance the conjugation process; AnteoX, an additive that reinforces battery binders helping maximize performance of silicon containing anodes; EuGeni, a COVID-19 antigen rapid test; and AnteoRelease and AnteoCoat. The company was formerly known as Anteo Diagnostics Limited and changed its name to AnteoTech Limited in November 2019. AnteoTech Limited is headquartered in Eight Mile Plains, Australia.
How the Company Makes MoneyAnteoTech Ltd generates revenue primarily through the commercialization of its AnteoBind technology. The company licenses this technology to partners and clients in various industries who integrate it into their product offerings, particularly in the fields of diagnostics and energy storage. Revenue streams include licensing fees, royalties from product sales that utilize AnteoBind, and direct sales of products incorporating the technology. Additionally, AnteoTech has formed strategic partnerships and collaborations that enhance its market reach and contribute to its earnings. These partnerships often involve joint development agreements or co-marketing efforts that bolster the company's presence in target markets.

AnteoTech Ltd Financial Statement Overview

Summary
AnteoTech Ltd is facing significant financial challenges with persistent losses and negative cash flows. Despite a stable equity base, increasing leverage and cash burn are critical concerns. Operational inefficiencies and inconsistent revenue growth further undermine financial stability.
Income Statement
35
Negative
AnteoTech Ltd's revenue growth shows inconsistency, with a decline from 2020 to 2021 and a slight increase in 2023. The company operates at a significant net loss, resulting in a negative net profit margin. Gross profit margins are positive, but the EBIT and EBITDA margins are deeply negative, indicating operational inefficiencies.
Balance Sheet
30
Negative
The company has maintained a stable equity base, but the debt-to-equity ratio has increased over the years, indicating rising leverage. The equity ratio is reasonable, reflecting a moderate level of risk, but the ongoing losses are eroding shareholder equity.
Cash Flow
40
Negative
AnteoTech Ltd experiences negative operating cash flow, indicating challenges in covering operational expenses. The free cash flow has shown some improvement but remains negative, reflecting ongoing cash burn. The company relies heavily on financing activities to support operations.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue460.40K365.72K760.88K898.07K299.40K
Gross Profit460.40K365.72K760.88K898.07K1.27M
EBITDA-11.57M-12.35M-12.07M-7.18M-4.10M
Net Income-8.88M-12.65M-10.72M-6.22M-3.13M
Balance Sheet
Total Assets9.38M5.36M15.26M23.68M3.91M
Cash, Cash Equivalents and Short-Term Investments5.03M2.72M10.10M21.39M3.21M
Total Debt2.31M1.31M1.03M1.28M134.87K
Total Liabilities4.08M2.99M2.91M2.56M699.63K
Stockholders Equity5.31M2.38M12.36M21.11M3.21M
Cash Flow
Free Cash Flow-7.58M-8.77M-11.77M-4.76M-2.77M
Operating Cash Flow-6.52M-8.08M-8.65M-4.55M-2.50M
Investing Cash Flow-1.06M-690.83K-3.12M-213.07K-270.45K
Financing Cash Flow9.89M1.39M482.29K22.94M1.71M

AnteoTech Ltd Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.02
Price Trends
50DMA
0.01
Positive
100DMA
0.01
Positive
200DMA
0.02
Positive
Market Momentum
MACD
<0.01
Negative
RSI
92.13
Negative
STOCH
119.05
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ADO, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and above the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 92.13 is Negative, neither overbought nor oversold. The STOCH value of 119.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ADO.

AnteoTech Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
AU$36.24M-36.95%11.11%
52
Neutral
$7.59B0.18-63.05%2.16%16.16%0.65%
50
Neutral
AU$64.65M-131.55%12.53%-11.04%
46
Neutral
$14.28M-64.72%139.19%33.33%
44
Neutral
AU$48.70M-140.07%62.15%33.93%
$24.49M-75.39%
$26.37M-43.63%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:ADO
AnteoTech Ltd
0.02
0.00
0.00%
CYYNF
Cynata Therapeutics Limited
0.08
-0.11
-57.89%
AU:PTX
Prescient Therapeutics Limited
0.04
0.00
0.00%
SPHRF
Starpharma Holdings Limited
0.06
0.00
0.00%
AU:AVE
Avecho Biotechnology Limited
AU:PIQ
Proteomics International Laboratories Ltd.
0.39
-0.52
-57.14%

AnteoTech Ltd Corporate Events

AnteoTech Ltd Announces Cessation of Securities
Jul 22, 2025

AnteoTech Ltd announced the cessation of several securities, including options that have either lapsed due to unmet conditions or expired without exercise. This development may impact the company’s capital structure and could influence investor perception, potentially affecting its market positioning and stakeholder confidence.

AnteoTech Partners with Black Diamond Structures for Advanced Battery Development
Jul 21, 2025

AnteoTech Ltd has signed a binding Term Sheet with Black Diamond Structures LLC to develop and commercialize an advanced battery product combining AnteoTech’s AnteoX™ and BDS’s MOLECULAR REBAR® technology. This collaboration aims to improve the electrochemical performance and structural integrity of high silicon anodes, targeting battery manufacturers incorporating more than 10% silicon by weight. The agreement sets the stage for a Joint Development Agreement, with production at BDS’s Texas facility and potential global expansion. This partnership is expected to accelerate value creation and deliver significant benefits to customers in the evolving LiB industry.

AnteoTech Achieves Key Milestone with Ultranode™ X Technology
Jul 17, 2025

AnteoTech Ltd has achieved a significant milestone with its Ultranode™ X technology, reaching 890 cycles with 80% capacity retention for a 70% silicon anode. This advancement positions AnteoTech to enhance battery performance, offering benefits such as increased energy density and reduced battery size. The company is leveraging its collaboration with Mercedes-Benz and targeting EV cell manufacturers, aiming to capitalize on the growing demand for high-performance batteries in various sectors, including EVs and medical devices.

AnteoTech Showcases High-Silicon Anode Innovations at AABC Europe
Jun 26, 2025

AnteoTech Ltd announced a presentation by its Chief Technology Officer, Manuel Wieser, at the 15th International Advanced Automotive Battery Conference in Mainz, Germany. The presentation, titled ‘Maximising high silicon anode performance,’ highlighted AnteoTech’s products, Anteo X™ and Ultranode™, which enhance anode integrity and support the development of next-generation high-silicon anodes for batteries. This development positions AnteoTech as a key player in the evolving automotive battery industry, aligning with the growing demand for efficient and sustainable battery technologies.

AnteoTech Ltd Reports Significant Growth and Strategic Collaborations in Life Sciences
Jun 12, 2025

AnteoTech Ltd’s Life Sciences Business Unit is on track to achieve approximately A$0.93 million in sales for FY2025, marking a 130% increase over the previous year. The company has received a significant order from the Serum Institute of India, reflecting growing demand and a strengthening relationship. Despite some delays in the Vidcare project due to regulatory requirements, AnteoTech continues to expand its collaborations, including successful prototype development for KOMA Biotech in South Korea. These developments underscore AnteoTech’s strategic efforts to deepen customer relationships and expand its market presence.

AnteoTech Ltd Unveils Strategic Review Outcomes to Boost Revenue and Market Expansion
Jun 10, 2025

AnteoTech Ltd has completed a strategic review resulting in significant organizational changes aimed at accelerating revenue generation and expanding market reach. Key outcomes include cost reductions, strategic partnerships, and a focus on commercializing existing products in rapidly growing markets such as E-mobility and life sciences across India, Europe, and the USA. These initiatives are expected to enhance AnteoTech’s market positioning and stakeholder trust, paving the way for future business expansion.

AnteoTech Appoints Interim CEO with Strategic Focus
May 8, 2025

AnteoTech Ltd has formalized an employment agreement with Ms. Merrill Gray, who has stepped into the role of Interim CEO and Managing Director from her previous position as a Non-Executive Director. The agreement, effective from April 16, 2025, to October 16, 2025, includes a base remuneration and a daily rate for CEO services, with performance-based incentives tied to strategic milestones. This leadership transition is expected to guide the company through its strategic review and align its operations with revised strategies, potentially impacting its market positioning and stakeholder interests.

AnteoTech Announces Director Departure and Shareholding Update
Apr 30, 2025

AnteoTech Ltd has announced the cessation of Mr. David Radford as a director effective April 22, 2025. Mr. Radford, through Lucremont Pty Ltd, holds significant interests in the company, including ordinary shares and a substantial number of unlisted options. This change in directorship may influence the company’s strategic direction and stakeholder interests, given Mr. Radford’s notable shareholding and involvement in the company.

AnteoTech Ltd Reports Quarterly Progress Amid Strategic Realignment
Apr 30, 2025

AnteoTech Ltd has released its quarterly cashflow report and activities update for the period ending March 31, 2025, highlighting significant developments in its advanced battery technologies and life sciences divisions. The company is advancing its Ultranode™ technology, targeting the consumer electronics and e-Mobility markets, and is engaged in evaluations with major global chemical companies and Mercedes-Benz. In life sciences, AnteoTech is pursuing increased orders from the Serum Institute of India and negotiations with Vidcare. The company is undergoing strategic and cultural reviews to align its resources for growth, with a focus on sales, marketing, and cost management. Despite challenges in the global EV market, AnteoTech remains committed to leveraging its innovative technology suite to unlock shareholder value.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 22, 2025